Center of Experiment Teaching, Shenyang Normal University, Shenyang, Liaoning 110034,China.
Food processing Institute, Liaoning Academy of Agricultural Sciences, Shenyang 110161, China.
Pharmacol Res. 2018 Jun;132:80-89. doi: 10.1016/j.phrs.2018.04.010. Epub 2018 Apr 17.
The aim of this study was to assess the comparative efficacy and safety of polysaccharides from Auricularia auricula (Huaier) for patients with gastrointestinal cancers (GICs) through a systematic review and network meta-analysis. We performed a network meta-analysis to identify evidence from clinical trials. We searched databases for publications up to February 2018. The prespecified primary efficacy outcomes were clinical therapeutic effects, which included the treatment response rate, 0.5-year overall survival rate, 1-year overall survival rate, 2-year overall survival rate, KPS improved rate and AFP decreased rate. The safety outcomes were the side effects of Huaier. The secondary efficacy outcome was immune function. Subgroup analyses and meta-regression were performed according to the various cancer types in all of the efficacy and safety outcomes. The study is registered with PROSPERO (CRD42018086481). A total of 33 trials, involving 2884 patients and 10 treatment arms, were eligible. Huaier significantly increased the treatment response rate (2.48, 1.83-3.35) and survival rate (0.5-year, 1-year and 2-year) and improved immune function without increasing the incidence of adverse effects. Significant efficacy was observed in most subgroups. Network meta-analysis revealed that Huaier was very suitable for combination therapy with TACE and I particle implantation. Similarly, Huaier also had a good adjuvant therapeutic effect on enhancing platinum (L-OHP and DDP) and adriamycin (ADM). Huaier offers clear advantages for patients with GICs. Moreover, patients should be encouraged to accept Huaier treatment, especially HCC patients undergoing combination therapy with TACE and I particle implantation.
本研究旨在通过系统评价和网络荟萃分析评估银耳多糖（Huaier）治疗胃肠道癌症（GIC）患者的疗效和安全性。我们进行了网络荟萃分析以确定来自临床试验的证据。我们检索了截至 2018 年 2 月的数据库中的出版物。预设的主要疗效结局是临床治疗效果，包括治疗反应率、0.5 年总生存率、1 年总生存率、2 年总生存率、KPS 改善率和 AFP 下降率。安全性结局是 Huaier 的副作用。次要疗效结局是免疫功能。根据所有疗效和安全性结局中的各种癌症类型进行亚组分析和荟萃回归。该研究已在 PROSPERO（CRD42018086481）上注册。共有 33 项试验，涉及 2884 名患者和 10 个治疗组，符合条件。银耳多糖显著提高了治疗反应率（2.48，1.83-3.35）和生存率（0.5 年、1 年和 2 年），并改善了免疫功能，而没有增加不良反应的发生率。在大多数亚组中观察到了显著的疗效。网络荟萃分析显示，银耳多糖非常适合与 TACE 和 I 粒子植入联合治疗。同样，银耳多糖对增强铂类（L-OHP 和 DDP）和阿霉素（ADM）也具有良好的辅助治疗作用。银耳多糖为 GIC 患者带来了明显的优势。此外，应鼓励患者接受银耳多糖治疗，尤其是接受 TACE 和 I 粒子植入联合治疗的 HCC 患者。
